Serotonin transporter (SERT) availability was assessed using 2 tracers, [¹¹C]N,N-dimethyl-2-(2-amino-4-cyanophenylthio)benzylamine ([¹¹C]DASB) and [¹¹C]N,N-dimethyl-2-(2-amino-4-fluoromethylphenylthio)benzylamine) ([¹¹C]MADAM), in independent cohorts of patients and controls. This study aimed to independently confirm whether SERT remains intact in nondepressed individuals with early-stage Parkinson disease (PD), because the use of diverse methodologies could potentially yield disparate results. Methods: Seventeen PD patients (5 women and 12 men; age, 64 ± 7 y; Unified Parkinson’s Disease Rating Scale motor score, 23 ± 5; Beck Depression Inventory score, 5 ± 4) and 20 age- and sex-matched healthy controls underwent [¹¹C]MADAM PET at Karolinska Institutet. Fifteen PD patients (5 women and 10 men; age, 59 ± 9 y; Unified Parkinson’s Disease Rating Scale motor score, 15 ± 7; Beck Depression Inventory score, 4 ± 4) and 8 controls were examined with [¹¹C]DASB PET at the University of British Columbia. PET scans were performed at both institutions using a high-resolution research tomograph. A simplified reference tissue model and Logan graphical analysis were used to calculate the regional nondisplaceable binding potential (BP_ND), using the cerebellum as the reference. Parametric BP_ND images were generated using wavelet-aided parametric imaging. MRI-defined volumes of interest included cortical and subcortical regions, as well as brain stem nuclei. Results: There were no significant differences between controls and early-stage PD patients in either the [¹¹C]DASB or the [¹¹C]MADAM cohort, regardless of the analysis method. Group differences (Cohen d) in the [¹¹C]DASB cohort ranged from 0.34 to 0.86 in brain stem nuclei, 0.09 to 0.61 in subcortical regions, and 0.28 to 0.70 in cortical regions. In the [¹¹C]MADAM cohort, they ranged from 0.16 to 0.40, 0.19 to 0.55, and 0.32 to 0.61, respectively. Logan BP_ND highly correlated with simplified reference tissue model BP_ND for both tracers in each group (P < 0.001). Conclusion: SERT availability is relatively preserved in nondepressed patients with PD. This study suggests that serotonergic degeneration is not a major feature of the disease in nondepressed patients with nonadvanced disease.

使用 2 种示踪剂 [¹¹C]N，N-二甲基-2-（2-氨基-4-氰基苯基硫基）苄胺 （^[11C]DASB） 和 [¹¹C]N，N-二甲基-2-（2-氨基-4-氟甲基苯硫基）苄胺） （^[11C]MADAM） 评估血清素转运蛋白 （SERT） 的可用性，在患者和对照的独立队列中。本研究旨在独立确认早期帕金森病 （PD） 非抑郁个体的 SERT 是否保持完整，因为使用不同的方法可能会产生不同的结果。方法：17 名 PD 患者 （5 名女性和 12 名男性;年龄 64 ± 7 岁;统一帕金森病评定量表运动评分，23 ± 5;贝克抑郁量表评分，5 ± 4） 和 20 名年龄和性别匹配的健康对照在卡罗林斯卡医学院接受了 [¹¹C]MADAM PET。15 名 PD 患者 （5 名女性和 10 名男性;年龄 59 ± 9 岁;统一帕金森病评定量表运动评分，15 ± 7;在不列颠哥伦比亚大学用 [¹¹C]DASB PET 检查了贝克抑郁量表评分 4 ± 4） 和 8 个对照。在两个机构都使用高分辨率研究断层扫描进行 PET 扫描。使用简化的参考组织模型和 Logan 图形分析来计算区域不可置换结合电位 （BP_ND），以小脑为参考。使用小波辅助参数成像生成参数 BP_ND 图像。MRI 定义的感兴趣体积包括皮质和皮质下区域，以及脑干核。 结果：无论分析方法如何，在 [¹¹C]DASB 或 [¹¹C]MADAM 队列中，对照组和早期 PD 患者之间均无显著差异。[¹¹C]DASB 队列中的组差异 （Cohen d） 范围为脑干核 0.34 至 0.86、皮质下区域 0.09 至 0.61 和皮质区域 0.28 至 0.70。在 [¹¹C] MADAM 队列中，它们的范围分别为 0.16 至 0.40、0.19 至 0.55 和 0.32 至 0.61。每组中两种示踪剂的 Logan BP_ND 与简化的参考组织模型 BP_ND 高度相关 （P < 0.001）。结论：SERT 可用性在非抑郁 PD 患者中相对保留。这项研究表明，5-羟色胺能变性并不是非晚期疾病非抑郁患者的主要特征。